FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292841355> ?p ?o ?g. }

• W4292841355 endingPage "754" @default.
• W4292841355 startingPage "754" @default.
• W4292841355 abstract "A 2016 review for the US Preventive Services Task Force (USPSTF) found use of statins for primary prevention of cardiovascular disease (CVD) was associated with reduced mortality and cardiovascular outcomes.To update the 2016 review on statins for primary prevention of CVD to inform the USPSTF.Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews (to November 2021); surveillance through May 20, 2022.Randomized clinical trials on statins vs placebo or no statin and statin intensity in adults without prior cardiovascular events; large cohort studies on harms.One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality.All-cause and cardiovascular mortality, myocardial infarction, stroke, composite cardiovascular outcomes, and adverse events.Twenty-six studies were included: 22 trials (N = 90 624) with 6 months to 6 years of follow-up compared statins vs placebo or no statin, 1 trial (n = 5144) compared statin intensities, and 3 observational studies (n = 417 523) reported harms. Statins were significantly associated with decreased risk of all-cause mortality (risk ratio [RR], 0.92 [95% CI, 0.87 to 0.98]; absolute risk difference [ARD], -0.35% [95% CI, -0.57% to -0.14%]), stroke (RR, 0.78 [95% CI, 0.68 to 0.90]; ARD, -0.39% [95% CI, -0.54% to -0.25%]), myocardial infarction (RR, 0.67 [95% CI, 0.60 to 0.75]; ARD, -0.85% [95% CI, -1.22% to -0.47%]), and composite cardiovascular outcomes (RR, 0.72 [95% CI, 0.64 to 0.81]; ARD, -1.28% [95% CI, -1.61% to -0.95%]); the association with cardiovascular mortality was not statistically significant (RR, 0.91 [95% CI, 0.81 to 1.02]; ARD, -0.13%). Relative benefits were consistent in groups defined by demographic and clinical characteristics, although data for persons older than 75 years were sparse. Statin therapy was not significantly associated with increased risk of serious adverse events (RR, 0.97 [95% CI, 0.93 to 1.01]), myalgias (RR, 0.98 [95% CI, 0.86 to 1.11]), or elevated alanine aminotransferase level (RR, 0.94 [95% CI, 0.78 to 1.13]). Statin therapy was not significantly associated with increased diabetes risk overall (RR, 1.04 [95% CI, 0.92 to 1.19]), although 1 trial found high-intensity statin therapy was significantly associated with increased risk (RR, 1.25 [95% CI, 1.05 to 1.49]). Otherwise, there were no clear differences in outcomes based on statin intensity.In adults at increased CVD risk but without prior CVD events, statin therapy for primary prevention of CVD was associated with reduced risk of all-cause mortality and CVD events. Benefits of statin therapy appear to be present across diverse demographic and clinical populations, with consistent relative benefits in groups defined by demographic and clinical characteristics." @default.
• W4292841355 created "2022-08-24" @default.
• W4292841355 creator A5001137551 @default.
• W4292841355 creator A5008583605 @default.
• W4292841355 creator A5052253657 @default.
• W4292841355 creator A5070109563 @default.
• W4292841355 creator A5070442023 @default.
• W4292841355 creator A5072458884 @default.
• W4292841355 creator A5088158435 @default.
• W4292841355 date "2022-08-23" @default.
• W4292841355 modified "2023-10-17" @default.
• W4292841355 title "Statin Use for the Primary Prevention of Cardiovascular Disease in Adults" @default.
• W4292841355 cites W1500963439 @default.
• W4292841355 cites W174544747 @default.
• W4292841355 cites W1965408926 @default.
• W4292841355 cites W1968240228 @default.
• W4292841355 cites W1976531866 @default.
• W4292841355 cites W1978614436 @default.
• W4292841355 cites W1999832762 @default.
• W4292841355 cites W2017872978 @default.
• W4292841355 cites W2018938059 @default.
• W4292841355 cites W2020043339 @default.
• W4292841355 cites W2031185570 @default.
• W4292841355 cites W2043263931 @default.
• W4292841355 cites W2043353709 @default.
• W4292841355 cites W2051160165 @default.
• W4292841355 cites W2061489988 @default.
• W4292841355 cites W2070410095 @default.
• W4292841355 cites W2073040540 @default.
• W4292841355 cites W2078919468 @default.
• W4292841355 cites W2088864641 @default.
• W4292841355 cites W2093138510 @default.
• W4292841355 cites W2094344282 @default.
• W4292841355 cites W2094418975 @default.
• W4292841355 cites W2097303364 @default.
• W4292841355 cites W2097364117 @default.
• W4292841355 cites W2097713945 @default.
• W4292841355 cites W2098034696 @default.
• W4292841355 cites W2101094196 @default.
• W4292841355 cites W2102006980 @default.
• W4292841355 cites W2103108681 @default.
• W4292841355 cites W2103946550 @default.
• W4292841355 cites W2105299596 @default.
• W4292841355 cites W2107295258 @default.
• W4292841355 cites W2118184073 @default.
• W4292841355 cites W2119605658 @default.
• W4292841355 cites W2125435699 @default.
• W4292841355 cites W2126563293 @default.
• W4292841355 cites W2126678006 @default.
• W4292841355 cites W2129670822 @default.
• W4292841355 cites W2129750583 @default.
• W4292841355 cites W2135631433 @default.
• W4292841355 cites W2135760109 @default.
• W4292841355 cites W2137983259 @default.
• W4292841355 cites W2146571866 @default.
• W4292841355 cites W2147161124 @default.
• W4292841355 cites W2153433045 @default.
• W4292841355 cites W2155598961 @default.
• W4292841355 cites W2164750952 @default.
• W4292841355 cites W2164819822 @default.
• W4292841355 cites W2168438443 @default.
• W4292841355 cites W2170127099 @default.
• W4292841355 cites W2313998826 @default.
• W4292841355 cites W2498871569 @default.
• W4292841355 cites W2552951299 @default.
• W4292841355 cites W2619015076 @default.
• W4292841355 cites W2751778625 @default.
• W4292841355 cites W2795841474 @default.
• W4292841355 cites W2800876320 @default.
• W4292841355 cites W2900034165 @default.
• W4292841355 cites W2905331745 @default.
• W4292841355 cites W3104495732 @default.
• W4292841355 cites W3118007133 @default.
• W4292841355 cites W4239424028 @default.
• W4292841355 cites W4292841355 @default.
• W4292841355 cites W4387669906 @default.
• W4292841355 doi "https://doi.org/10.1001/jama.2022.12138" @default.
• W4292841355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35997724" @default.
• W4292841355 hasPublicationYear "2022" @default.
• W4292841355 type Work @default.
• W4292841355 citedByCount "29" @default.
• W4292841355 countsByYear W42928413552022 @default.
• W4292841355 countsByYear W42928413552023 @default.
• W4292841355 crossrefType "journal-article" @default.
• W4292841355 hasAuthorship W4292841355A5001137551 @default.
• W4292841355 hasAuthorship W4292841355A5008583605 @default.
• W4292841355 hasAuthorship W4292841355A5052253657 @default.
• W4292841355 hasAuthorship W4292841355A5070109563 @default.
• W4292841355 hasAuthorship W4292841355A5070442023 @default.
• W4292841355 hasAuthorship W4292841355A5072458884 @default.
• W4292841355 hasAuthorship W4292841355A5088158435 @default.
• W4292841355 hasBestOaLocation W42928413551 @default.
• W4292841355 hasConcept C126322002 @default.
• W4292841355 hasConcept C127413603 @default.
• W4292841355 hasConcept C142724271 @default.
• W4292841355 hasConcept C168563851 @default.
• W4292841355 hasConcept C1862650 @default.
• W4292841355 hasConcept C197934379 @default.

• next